Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

What a perfect start to Worlds 2025 – T1 vs. Invictus Gaming was an absolute spectacle! Here's a summary of the games and the results at the bottom! IG Bans: Bard, Azir, Jarvan IV/Caitlyn, Ziggs T1 ...

Riot Games regularly adds new champions to the free-to-play MOBA game League of Legends, allowing you to take part in the battle for the Summoner's Rift. There are currently over 170 characters to ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

Former Vice President Atiku Abubakar, 2023 Labour Party presidential candidate Peter Obi, former Senate President David Mark and other coalition leaders have officially adopted the African Democratic ...

Lieutenant Commander Yashasvi Solanki, 27, has been appointed as the first female Aide-de-Camp (ADC) to the President of India, Droupadi Murmu. This appointment has marked a significant milestone for ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and toxicity challenges of current ADCs—and rapidly grow the multibillion-dollar ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...